Form 4: Zenas BioPharma Director, John J Orloff, Reports Stock Option Grant

Director John J Orloff reports the acquisition of stock options in Zenas BioPharma, Inc.

Summary

• On September 12, 2024, John J Orloff, a director of Zenas BioPharma, Inc. [ZBIO], was granted stock options to purchase 18,500 shares of common stock.
• The exercise price of the options is $17.
• The options vest 100% on September 12, 2025, subject to continued service.
• The options expire on September 11, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative. It's a neutral event in the normal course of business.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

There are no explicit forward-looking statements in this document.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biopharmaceutical companies.
• The vesting schedule of one year is fairly typical, as it incentivizes continued service to the company.
• The number of shares granted and the exercise price would need to be compared to similar companies of comparable size and stage of development to determine if they are in line with industry standards.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders if the options are exercised in the future.

Key Dates